UNITED THERAPEUTICS CORP

CEO insider trades show United Therapeutics’ confidence in rising EBITDA, amid value‑based contracts, supply‑chain stress, and a strong 18.2% margin outlook.

United Therapeutics shares: CEO’s option exercise, conversion and structured sales reveal clear, compliant insider activity and market‑impact‑minimizing liquidity management.

United Therapeutics’ recent insider trades show strong liquidity, stable pricing, and solid growth potential in the rare‑disease biotech space.

Discover how United Therapeutics’ insider trades reveal governance strength and strategic moves to master value‑based reimbursement, cost‑efficiency, and supply‑chain resilience for cutting‑edge biotech therapies.

United Therapeutics execs buy, sell, and plan a Rule 144 sale—insider moves reveal portfolio strategy, market confidence, and potential liquidity impact.

United Therapeutics’ recent Form 4 shows a strategic option exercise, trust‑based tax planning, and concentrated voting power—insights for investors and regulators.

United Therapeutics (UTHR) shares surge to 33.5% ownership after a 9,500‑option exercise and multi‑day sales—see the SEC 10(b)(5) filing that details the strategy and impact.

United Therapeutics insider trading: CEO Martine A. Rothblatt’s trust‑based trades show disciplined equity management, hinting at future pipeline milestones and investor confidence.

United Therapeutics’ July 29 Form 4 shows CEO trades within SEC‑approved windows while the company advances inhaled prostacyclin, CRISPR‑AAV PAP, and a lung‑cancer immunotherapy combo.

United Therapeutics insider trades: Martine Rothblatt’s 10(b)(5) buys and sells show confidence in the firm’s pipeline and strategic liquidity management while keeping ownership stable.